The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

Dr Singh, Gill Harinder Harry   (Principal Investigator (PI))

Professor Kwong Yok Lam   (Co-Investigator)

36

2021-11-01

1009872

The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

Acute promyeloyctic leukaemia, Arsenic trioxide, Asia, Outcome

Others - Medicine, Dentistry and Health

08191946

Health and Medical Research Fund - Full Grant

2020

On-going

(1) Objectives: 1. To establish a clinical registry of acute promyelocytic leukaemia (APL) in Asia. 2. To determine the epidemiologic and clinicopathologic features of APL in Asia. 3. To determine outcome of APL in Asia. 4. To compare the treatment outcome of patients with newly-diagnosed or relapsed APL treated with oral arsenic trioxide-based regimen versus those treated with other regimens across Asia. (2) Hypothesis to be tested: NA (3) Design and subjects: This is a retrospective-prospective cohort study of all patients diagnosed with APL since 2010 in Hong Kong and participating centres in Asia from Singapore, Malaysia, Zhejiang Province, Taipei, Bangkok and India. (4) Instruments: NA (5) Interventions: NA (6) Main outcome measures: The primary outcome measures in this study include the overall survival (OS), the relapse-free survival (RFS) and event-free survival (EFS). Secondary outcome measures include prognostic indicators (including the impact of different treatment regimens) for OS, RFS and EFS; outcome following relapse and impact of haematopoietic stem cell transplantation following second remission. (7) Data analyses: Propensity score analysis will be employed to study the impact of different therapeutic approaches in APL. (8) Expected results: With the long-term data of oral arsenic trioxide-based regimen for APL available from Hong Kong, retrospective and prospective comparison with other treatment approaches will generate important information, which may form the basis for the pioneer use of oral arsenic trioxide outside Hong Kong.